Gilreath & Associates Press Releases
Allograft Implant Litigation
In recent years, the FDA discovered that some of the nation's most prominent human tissue transplant companies have been defying federal safety regulations for their own profit. The FDA uncovered evidence of improper handling, screening, and acquisition of harvested skin, bone and soft tissue allograft material, which is dispersed for transplantation into patients across the nation. These negligent and reprehensible actions in the billion-dollar tissue transplant industry have put many allograft recipients at risk for developing serious medical conditions.
Information Regarding Allograft and Allograft Litigation Request Review of Your Allograft Implant Allograft Litigation News.
Contact our Tennessee product liability attorneys today for your free consultation.
Tricks of the Trade - How Insurance Companies Deny, Delay, Confuse and Refuse
Effective Use of Federal Motor Carrier Safety Regulations
